SARS-CoV-2-related atypical thyroiditis by I. Muller et al.
 1 
SARS-CoV-2-related atypical thyroiditis 1 
Ilaria Muller MD PhD1,2, Daniele Cannavaro MD3, Davide Dazzi MD4, Danila Covelli MD1, 2 
Giovanna Mantovani MD PhD1,3, Antonio Muscatello MD5, Emanuele Ferrante MD1, Emanuela Orsi 3 
MD1, Veronica Resi MD1, Virgilio Longari MD6, Marco Cuzzocrea MD6, Alessandra Bandera MD 4 
PhD5,7, Elisa Lazzaroni MD1, Alessia Dolci MD1, Ferruccio Ceriotti MD8, Tiziana E Re MD9, 5 
Andrea Gori MD5,7, Maura Arosio MD PhD1,3, Mario Salvi MD1 6 
 7 
1 Endocrinology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy  8 
2 Thyroid Research Group - Division of Infection & Immunity, Cardiff University School of 9 
Medicine, Cardiff, UK 10 
3 Department of Clinical Sciences and Community Health, University of Milan, Italy   11 
4 Internal Medicine, Ospedale di Vaio, Fidenza, Italy 12 
5 Infectious Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 13 
6 Nuclear Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 14 
7 Department of Pathophysiology and Transplantation, University of Milan, Italy  15 
8 Clinical Laboratory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 16 
9 Medicine - Acute Medical Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 17 
Milan, Italy 18 
CORRESPONDING AUTHOR 19 
Dr Ilaria Muller 20 
Endocrinology (UOC Endocrinologia) 21 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico 22 
Via Francesco Sforza 35, 23 
20122 Milan, Italy 24 
Email: ilaria.muller@policlinico.mi.it 25 
Phone: +39 02 55033332, Fax: +39 02 50320605  26 
This is the peer reviewed version of the article published online 30 July 2020 in final form in The Lancet 
Diabetes & Endocrinology, DOI https://doi.org/10.1016/S2213-8587(20)30266-7, found at 
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30266-7/fulltext. This article has been accepted for 
publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and 
proofreading process which may lead to differences between this version and the Version of Record." 
 2 
The Covid-19 pandemic determined by the severe acute respiratory syndrome (SARS) 27 
coronavirus 2 (SARS-CoV-2)1,2 is a global emergency that has seriously affected Northern Italy, 28 
where we are based. Preliminary data analysis of Covid-19 patients hospitalised in our Institution 29 
requiring high intensity of care (HICU), frequently showed low-suppressed serum thyroid 30 
stimulating hormone (TSH), with and without elevated free thyroxine (FT4) concentrations, 31 
suggestive for thyrotoxicosis. It is known that critically ill patients often show alterations of thyroid 32 
function tests known as non-thyroidal illness syndrome (NTIS)3,4. Alternatively, thyrotoxicosis might 33 
result from SARS-CoV-2 directly infecting the thyroid gland as described in other viral infections. 34 
This event is known as subacute thyroiditis and is characterised by self-limiting thyrotoxicosis of 35 
variable duration (weeks/months), followed by hypothyroidism with final restoration of 36 
euthyroidism5,6. 37 
In this study, we aimed to assess the prevalence of thyrotoxicosis, suggestive for subacute 38 
thyroiditis, in patients admitted in HICU units in relation to the presence or absence of Covid-19, by 39 
comparing HICU patients hospitalised in 2020 for Covid-19 disease (HICU-20), with those 40 
hospitalised in the same HICU units in 2019, thus SARS-CoV-2 negative (HICU-19). Considering a 41 
0.5% prevalence of subacute thyroiditis in HICU-19, in line with general population5, and a 10% 42 
estimated prevalence in HICU-20 patients, a total of 166 patients were needed to obtain a 80% 43 
statistical power and a significance of 0.05 (two tails). 44 
Thyroid function was assessed at hospital admittance (within two days average) in 93 HICU-45 
20 and 101 HICU-19 consecutive patients hospitalised for Covid-19 disease. Fifty-two Covid-19 46 
patients hospitalised in low intensity of care units (LICU-20) were also studied (Table 1A 47 
appendix). HICU-20 patients were younger (65.312.9 years, P<0.01) and predominantly male 48 
(68.8%, P=0.04) compared with HICU-19 (73.015.2 years, 56.4%) and LICU-20 patients 49 
(70.318.1 years, 48.1%). Consistently with the known female preponderance of thyroid disease, 50 
patients with pre-existing thyroid disorders (N=42) were more frequent in HICU-19 (22.8%) and 51 
LICU-20 (21.1%) compared with HICU-20 (8.6%, P=0.02), and were excluded from the thyroid 52 
 3 
function analysis (Table 1B appendix). As many as 13/85 (15.3%) HICU-20 patients were 53 
thyrotoxic, compared to 1/78 (1.3%) HICU-19 (P<0.01) and 1/41 (2.4%) LICU-20 (P=0.02). Among 54 
Covid-19 thyrotoxic patients, 9/14 (64.3%) were men and 5/14 (35.7%) women (P=0.02). Serum 55 
TSH concentrations were skewed towards lower values in HICU-20 compared with HICU-19 and 56 
LICU-20 patients (P<0.02, Figure 1A). Mean serum FT4 concentrations were higher in HICU-20 57 
than LICU-20 (P<0.02), but not HICU-19 patients (P=0.38; Table 1B appendix). Stratification for 58 
sex and age did not affect the results (not shown). Although the dramatic increase of patients 59 
requiring hospitalization due to the Covid-19 pandemic emergency may have selected HICU-20 60 
patients in more critical conditions compared with HICU-19, the thyroid dysfunction observed in 61 
HICU-20 patients unlikely relates to NTIS only. Serum FT3 concentrations, the main NTIS 62 
indicator, were in fact low in all groups, not only HICU-20 (P=0.71; Table 1B appendix). 63 
Furthermore, in NTIS normal/low serum concentrations of TSH and T3 are usually associated with 64 
low concentrations of T43,4, but not normal/elevated as observed in our patients. A transient (hours) 65 
T4 increase may occur in acute conditions, usually associated with normal/high serum TSH 66 
concentrations3, but not low as observed in this study. It is plausible that our patients may have a 67 
combination of thyrotoxicosis and NTIS, described as T4 thyrotoxicosis4. 68 
To elucidate the diagnostic hypothesis, eight Covid-19 patients with any thyroid dysfunction 69 
observed at hospital admission were followed-up after a mean of 51 days, when discharged and 70 
negative for SARS-CoV-2 (Table 2 appendix). Two were confirmed hypothyroid and had typical 71 
marked diffuse hypoechogenicity and heterogeneity at thyroid ultrasound, consistent with 72 
autoimmune thyroiditis. All other patients with low/suppressed TSH or thyrotoxicosis at baseline had 73 
normal thyroid function and negative thyroid autoantibodies at follow-up; none reported neck pain 74 
ever. All had a diffuse mild hypoechoic pattern at thyroid ultrasound; focal markedly hypoechoic 75 
areas were present in 3/6 (50%) cases. Such areas corresponded to focal reduced uptake at SPECT 76 
imaging, and the thyroid gland showed a general low-normal or reduced 99mTc uptake, suggestive for 77 
subacute thyroiditis (Figure 2 appendix). It is plausible that we may have missed some typical 78 
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imaging features of subacute thyroiditis in the other three patients, due to the time elapsed between 79 
hospital admission and follow-up, and the anti-inflammatory treatments received. 80 
This study suggests that a substantial proportion of Covid-19 patients, requiring high intensity 81 
of care, present with thyrotoxicosis and low serum TSH concentrations, likely as a consequence of 82 
subacute thyroiditis induced by SARS-CoV-2, in an underlying setting of NTIS. They also had a 83 
lower prevalence of pre-existing thyroid disorders (autoimmune and not) compared with HICU-19 84 
patients; this suggests that such conditions are not a risk factor for Covid-19 disease. In these 85 
patients, serum FT4 concentrations were not as elevated, and serum TSH concentrations not as 86 
suppressed, as classically described in subacute thyroiditis6. These patients also did not complain of 87 
neck pain, consistent with silent thyroiditis, did not have leucocytosis, but had lymphopenia as 88 
observed with Covid-19 infection (Table 2 appendix)2. These features differ from those described in 89 
a single case report of late-onset thyroiditis after mild SARS-CoV-2 infection7 and in classic 90 
subacute thyroiditis, characterised by a pathognomonic infiltration of giant cells (congregates of 91 
lymphocytes, histiocytes and colloid) with swelling of thyroid follicles, stretching of thyroid capsule 92 
and consequent neck pain6. Rather, in SARS-CoV-2 induced thyroiditis giant cells might not form 93 
due to lymphopenia, and thyroid cells may be damaged by apoptosis as observed with SARS-94 
associated coronavirus (SARS-CoV)8. The angiotensin-converting enzyme 2 (ACE-2) is a host-cell 95 
entry receptor for both SARS-CoV and SARS-CoV-21 and might be in part responsible for a 96 
common pathogenic pathway. ACE-2 is even more highly expressed in thyroid than lung cells, and 97 
in women such expression negatively correlates with signatures of immune cell enrichment9. This 98 
might in part explain why in this study the most severe forms of Covid-19 pneumonia2, and 99 
associated thyroid dysfunction, affected predominantly men (HICU-20), but not women as in the 100 
classic viral subacute thyroiditis6. 101 
The serum CRP concentration is a general non-specific marker of inflammation, subacute 102 
thyroiditis10 and Covid-19 disease severity2. Median serum CRP concentrations were significantly 103 
higher in HICU-20 compared with HICU-19 ad LICU-20 patients (P<0.01; Figure 1B, Table 1B 104 
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appendix). In Covid-19 patients, serum CRP, but not TSH and FT4 concentrations, were 105 
significantly higher in deceased patients than in survivors (median[IQR] 190[94 - 256] mg/L vs 106 
73[33 - 136] mg/L respectively, P<0.01). This difference was not observed in HICU-19 patients 107 
(P=0.27). It could be speculated that patients with higher serum CRP concentrations may have a 108 
systemic spread of SARS-Cov-2, that is more likely to affect the thyroid gland. 109 
This study has some limitations: i) serum FT4/FT3 concentrations were measured only in 110 
case of abnormal TSH; ii) thyroid imaging was conducted nearly two months after baseline TSH 111 
measurement because of prolonged post-discharge persistence of SARS-Cov-2 positivity; iii) serum 112 
TSH was not available in all LICU patients. This study has several strengths: i) first comprehensive 113 
description of thyroid alterations in hospitalised Covid-19 patients; ii) focused study design; iii) 114 
initial longitudinal follow-up. 115 
In conclusion, we suggest to routinely assess thyroid function in patients affected with Covid-116 
19 requiring high intensity of care, because they frequently present with thyrotoxicosis due to a 117 
peculiar form of subacute thyroiditis induced by SARS-CoV-2. Considering the currently ongoing 118 
pandemic emergency, future studies are encouraged to confirm, or counter, these results. Thyroid 119 
cytology or histology and longitudinal studies of thyroid (dys)function in these patients would be 120 
particularly informative. 121 
CONTRIBUTORS’ STATEMENT 122 
IM, MS, DCa, DD, DCo, GM and MA contributed to study conception and design, literature search, 123 
data collection, data analysis, data interpretation, figures and manuscript writing. 124 
VL, MC contributed to data collection, data analysis, data interpretation, figures and manuscript 125 
writing. 126 
AM, EF, EO, VR, AB, EL, AD, FC, TR, AG contributed to data collection, data analysis, data 127 
interpretation and manuscript writing. 128 
 6 
DISCLOSURE STATEMENT 129 
Authors have nothing to disclose. 130 
  131 
 7 
REFERENCES 132 
1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus 133 
of probable bat origin. Nature 2020; 579(7798): 270-3. 134 
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. 135 
N Engl J Med 2020; 382(18): 1708-20. 136 
3. Van den Berghe G. Non-thyroidal illness in the ICU: a syndrome with different faces. 137 
Thyroid 2014; 24(10): 1456-65. 138 
4. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. 139 
Lancet D & E 2015; 3(10): 816-25. 140 
5. Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J 2009; 6: 5. 141 
6. Guimarães VC. Subacute and Riedel's Thyroiditis. In: Jameson JL, De Groot LJ, eds. 142 
Endocrinology Adult and Pediatric. 7 ed. Philadelphia: Elsevier Saunders; 2016: 1528-39. 143 
7. Brancatella A, Ricci D, Viola N, Sgro D, Santini F, Latrofa F. Subacute thyroiditis after 144 
SARS-CoV-2 infection. J Clin Endocrinol Metab 2020; 105(7): 1-4. 145 
8. Wei L, Sun S, Xu CH, et al. Pathology of the thyroid in severe acute respiratory syndrome. 146 
Hum Pathol 2007; 38(1): 95-102. 147 
9. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 148 
in a wide variety of human tissues. Infect Dis Poverty 2020; 9(1): 45. 149 
10. Pearce EN, Bogazzi F, Martino E, et al. The prevalence of elevated serum C-reactive protein 150 
levels in inflammatory and noninflammatory thyroid disease. Thyroid 2003; 13(7): 643-8. 151 
  152 
 8 
FIGURES 153 
 154 
Figure 1: Graphical representation of the main thyroid-related laboratory findings in the three 155 
groups of patients (excluded those with known thyroid disorders at hospitalisation). 156 
 157 
HICU-19 = high intensity of care units in 2019 (N=78). HICU-20 = high intensity of care units in 158 
2020 (N=85). LICU-20 = low intensity of care units in 2020 (N=41). 159 
A: Distribution of serum thyroid stimulating hormone (TSH) concentrations (mIU/L), expressed as 160 
median (IQR): 1.43 (0.88 - 2.37) mIU/L in HICU-19, 1.04 (0.47 - 1.80) mIU/L in HICU-20 and 1.43 161 
(0.71 - 2.28) in LICU-20 (p<0.02), with differences between HICU-20 and HICU-19 being highly 162 
significant (P<0.01) and between HICU-20 and LICU-20 moderately significant (P<0.05). 163 
B: Box plots of median [IQR] CRP concentrations in HICU-19 (66 [15 - 121] mg/L), HICU-20 (96 164 
[51 - 177] mg/L) and LICU-20 patients (52 [22 - 103] mg/L) (P<0.01). 165 
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APPENDIX 
METHODS 
STUDY DESIGN AND PATIENTS 
This is a single centre observational study with a longitudinal component. Consecutive 
patients hospitalised for Covid-19 from March 3rd to April 28th 2020 in HICU (HICU-20) and LICU 
(LICU-20) units and, as controls, in the same HICU units during the equivalent period of 2019 
(HICU-19), were included in the study, as they had serum TSH routinely measured at hospital 
admittance. Patients with severe respiratory distress received predominantly oxygen supply in LICU 
and Continuous Positive Airway Pressure (CPAP) in HICU units; in LICU and HICU units a 
minority of patients were treated with intubation and invasive mechanical ventilation.  
The electronic clinical records of HICU-19, HICU-20 and LICU-20 patients were then 
analysed for clinical and pharmacological history, length of hospitalisation and final outcome. 
Patients with no available clinical data were excluded from the study. Patients with known history of 
any thyroid disease (autoimmune or not) before hospital admittance were also excluded from the 
analyses addressing the main study endpoints. 
HICU-20 and LICU-20 patients showing abnormal thyroid function tests at hospital 
admittance were contacted for follow-up after discharge when negative at SARS-CoV-2 test and 
after providing informed consent. The follow-up visit included biochemical tests and ultrasound scan 
of the thyroid gland using a MyLab™25Gold ultrasound machine (Esaote, Genoa, Italy). Thyroid 
scintigraphy with 99m-technetium-pertechnetate (99mTc) and SPECT tomographic acquisitions of 
thyroid gland (triple head gamma camera, Irix, Philips Medical Systems, US) was also performed as 
a functional test in patients showing focal hypoechoic areas at ultrasound.  
This study, named "Tiro-Covid-19", was approved by the Ethics Committee of Milano Area 2 
(Milan, Italy), ID 375_2020. 
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BIOCHEMICAL ANALYSIS 
Serum thyroid-stimulating hormone (TSH), free-thyroxine (FT4) and free-triiodothyronine 
(FT3) concentrations were measured by electrochemiluminescence immunoassay (Cobas® e801, 
Roche Diagnostics, Germany). Reference intervals were 0.28 – 4.30 mIU/L for TSH, 10.3 - 21.9 
pmol/L for FT4 and 3.1 - 7.7 pmol/L for FT3. As per the automated setting of the hospital laboratory, 
FT4 and FT3, or FT4 only, were measured for TSH concentrations <0.45 mIU/L or >3.50 mIU/L, 
respectively. The serum C reactive protein (CRP) was measured by turbidimetry (Cobas® c702, 
Roche Diagnostics, Germany) and considered normal if <5 mg/L. 
The follow-up measurements included TSH, FT4, FT3, CRP, full blood count (XN-9000TM, 
Sysmex, US), autoantibodies to thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) by enzyme-
linked immunosorbent assay (ThermoFisher, US) and autoantibodies to TSH receptor (TRAb) by 
Immulite 2000/2000 XPi TSI (Siemens, Germany). Normal reference ranges were <35 KIU/L 
(TPOAb), <60 KIU/L (TgAb) and <0.55 KIU/L (TRAb). 
 
STUDY ENDPOINTS 
Patients with TSH <0.28 mIU/L and/or FT4 >21.9 pmol/L concentrations were classified as 
“thyrotoxic”, whereas those with TSH <0.45 mIU/L (laboratory automatic cut-off) were classified as 
“low TSH”. Patients with TSH >4.30 mIU/L (and FT4 ≤21.9 pmol/L) and/or FT4 <10.3 pmol/L 
concentrations were classified as “hypothyroid”. 
The primary study endpoint was the prevalence of thyrotoxicosis, suggestive for subacute 
thyroiditis, in patients admitted in HICU in relation with presence or absence of Covid-19, thus 
comparing HICU-20 and HICU-19. We also studied: i) the prevalence of thyrotoxicosis in less 
critical Covid-19 patients LICU-20, ii) thyroid (dys)function of Covid-19 patients in relation with 
inflammatory markers such as the C reactive protein (CRP), length of hospitalization and patient’s 
outcome. 
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STATISTICAL ANALYSIS 
Variables were assessed for their distribution and summarized using the sample mean ± 
standard deviation (SD) when approximately normally distributed, or using the sample median and 
interquartile range (IQR) otherwise. Categorical variables were summarized using percentages, and 
the statistical significance of associations between them calculated using Fisher’s exact test. The 
Kruskal-Wallis test with Mann-Whitney U tests or one-way analysis of variance (ANOVA) with post 
hoc Bonferroni correction were also applied, depending on the distribution of variables. The 
Spearman’s rank correlation coefficient was used for non parametric data to analyse the relationship 
between biochemical parameters. The data were analysed in STATA, version 12 (StataCorp LLC, 
US). P values <0.05 were considered statistically significant.  
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TABLES 
Table 1: Clinical characteristics of patients hospitalised in units of high intensity of care during 
(HICU-20) and in absence (HICU-19) of Covid-19 pandemic, and of low intensity of care 
during Covid-19 pandemic (LICU-20). 
 
        
 
 
HICU-19 
Covid-NEG 
HICU-20 
Covid-POS 
LICU-20 
Covid-POS 
ALL 
3 
GROUPS 
HICU-20 
vs 
HICU-19 
HICU-20 
vs 
LICU-20 
        
A  N = 101 N = 93 N = 52 P P P 
        
        
Age                                          years 73.0  15.2 65.3  12.9 70.3  18.1 <0.01 <0.01 0.06 
Female                                    N (%) 44 (43.6%) 29 (31.2%) 27 (51.9%) 0.04 0.08 0.01 
Length of hospitalisation         days 20.9  15.8 23.8  15.8 22.3  15.5 0.44 0.20 0.60 
Deaths 1                                  N (%) 12/101 (11.9%) 17/91 (18.7%) 4/51 (7.8%) 0.16 0.18 0.08 
Known thyroid disorders       N (%) 23 (22.8%) 8 (8.6%) 11 (21.1%) 0.02 <0.01 0.03 
        
        
        
B  N = 78 N = 85 N = 41 P P P 
        
        
Thyrotoxicosis 2             N (%) 1 (1.3%) 13 (15.3%) 1 (2.4%) <0.01 <0.01 0.02 
Suppressed TSH 3          N (%) 1 (1.3%) 8 (9.4%) 1 (2.4%) 0.04 0.02 0.15 
Low TSH 4                     N (%) 6 (7.7%) 21 (24.7%) 4 (9.8%) <0.01 <0.01 <0.05 
Hypothyroidism 5           N (%) 7 (9.0%) 3 (3.5%) 4 (9.8%) 0.28 0.51 0.59 
TSH mIU/L  
median (IQR) 
[range] 
1.43 (0.88 - 2.37) 
[0.17 - 14.00] 
1.04 (0.47 - 1.80) 
[0.06 - 10.30] 
1.43 (0.71 - 2.28) 
[0.27 - 10.10] 
<0.02 <0.01 <0.05 
FT4 pmol/L 6 
mean ± SD 
[range] 
16.2  2.4 
[10.8 - 20.1] 
18.7  5.4 
[8.5 - 32.3] 
13.5  4.6 
[4.5 - 19.2] 
<0.02 0.38 <0.02 
FT3 pmol/L 7 
mean ± SD 
[range] 
2.6  0.8 
[1.4 - 3.5] 
2.9  0.6 
[2.0 - 3.8] 
2.9  1.1 
[1.8 - 4.0] 
0.71 0.50 0.76 
CRP mg/L 
median (IQR) 
[range] 
66 (15 - 121) 
[1 - 400] 
96 (51 - 177) 
[5 - 410] 
52 (22 - 103) 
[0 - 243] 
<0.01 <0.01 <0.01 
        
 
Data are presented as mean ± SD or median (IQR), based on normal or non-normal distribution respectively. 
1 Percentages calculated on denominators after excluding patients still hospitalised at the time of data analysis: 2/93 
(2.1%) HICU-20 and 1/52 (1.9%) LICU-20 
2 Defined as TSH <0.28 mIU/L and/or FT4 >21.9 pmol/L 
3 Defined as TSH <0.28 mIU/L 
4 Defined as TSH <0.45 mIU/L 
5 Defined as TSH >4.30 mIU/L (and FT4 ≤21.9 pmol/L) and/or FT4 <10.3 pmol/L 
6 FT4 measured only in patients with TSH <0.45 mIU/L or >3.50 mIU/L (N = 49)  
7 FT3 measured only in patients with TSH <0.45 mIU/L (N = 28) 
A = 102 HICU-19, 95 HICU-20 and 61 LICU-20 were initially evaluated; one HICU-19, two HICU-20 and nine LICU-
20 had no associated electronic clinical records, thus were excluded from the study. Serum TSH concentrations were 
routinely measured in all patients in HICU but less frequently in LICU units, due to different standard protocols applied 
at hospital admittance. All HICU-20 and LICU-20 patients were hospitalised for Covid-19 related pneumonia and 
respiratory distress. Diagnosis at hospitalisation in HICU-19 patients was pneumonia (34.6%), other respiratory diseases 
(14.8%), infections/sepsis (12.9%), cardiovascular (9.9%), abdominal (8.9%) and neurological (7.9%) disorders, trauma 
or haemorragia (7.0%), kidney failure and electrolyte disequilibrium (4.0%). Evidence of viral infection was reported in 
16 HICU-19 patients: 7 Influenza A virus, 4 Rhinovirus (in one case associated with influenza B virus), 3 Respiratory 
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Syncytial Virus RSV (in one case associated with metapneumovirus MPV), 1 viral meningitis not better specified, 1 
vasculitis related to HBV. 
B = Patients studied after excluding those with pre-existing thyroid disorders. Abbreviations in alphabetical order: CRP = 
C reactive protein. FT3 = Free tri-iodothyronine. FT4 = Free thyroxine. TSH = Thyroid Stimulating Hormone. 
History of steroids started prior to hospital admission was investigated to exclude its potential influence on thyroid 
function, and found present in 8 HICU-19, 3 HICU-20 and 6 LICU-20 patients, as treatment for several pre-existing 
disorders including: previous transplantation, rheumatoid arthritis, polymyalgia rheumatica, dermatitis/eczema, 
pneumonia, prostate cancer, hemolytic anemia, sarcoidosis, cryoglobulinemic vasculitis, pemphigus. The median daily 
dose was prednisone 5 mg. These 17 patients had normal thyroid function, except for one thyrotoxic patient (HICU-20; 
prednisone 5 mg daily) and one hypothyroid patient (LICU-20; prednisone 1 mg daily). Considering the small number of 
patients receiving steroids, predominantly low doses, before baseline assessment, we exclude that such treatment may 
have influenced the conclusions of the present study. 
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Table 2: Follow-up clinical parameters of patients hospitalised for Covid-19 showing thyroid dysfunction at admittance  
 
                         
    BASELINE - INPATIENT INITIAL FOLLOW-UP 
ID GROUP Sex Age TSH FT4 FT3 CRP WBC LYMPH THERAPY Days TSH FT4 FT3 CRP WBC LYMPH AbTg AbTPO TRAb 
Thyroid US 
focal hypo- 
ecoic areas 
Thyroid 
  99mTc 
uptake years mIU/L pmol/L pmol/L mg/L 10
9/L 109/L H A+M AV F.Up1 mIU/L pmol/L pmol/L mg/L 109/L 109/L KIU/L KIU/L KIU/L 
                         
 12 HICU-20 M 68 0.19 32.3 2.6 218 9.0 0.6 X X  18 1.26 18.9 2.5 1 10.5 1.3 NEG NEG NEG NA NA 
2 HICU-20 F 59 0.28 15.3 2.9 109 9.8 1.0 X  X 68 0.96 10.5 4.3 1 5.3 2.0 NEG NEG NEG NO NA 
3 LICU-20 M 24 0.33 9.6 4.0 10 5.9 1.4    46 1.17 10.4 4.9 1 9.2 2.5 NEG NEG NEG YES YES 
4 HICU-20 F 70 0.34 18.5 3.1 139 6.4 0.7 X  X 56 1.80 13.1 3.8 1 5.1 1.5 NEG NEG NEG NO NA 
5 HICU-20 M 61 0.40 16.0 3.8 17 6.0 1.1 X  X 56 0.93 13.5 4.6 4 6.3 1.9 NEG NEG NEG NO NA 
6 LICU-20 F 59 0.40 16.6 2.3 233 7.3 0.4 X X X 62 2.07 10.7 5.1 1 4.3 1.7 NEG NEG NEG YES YES 
7 HICU-20 M 66 0.43 22.8 NA 52 6.1 0.9 X  X 42 0.63 16.5 4.8 1 2.7 1.3 NEG NEG NEG YES YES 
8 HICU-20 F 78 8.09 22.8 NA 17 9.7 2.3 X  X 59 6.71 17.4 4.8 1 8.4 1.7 NEG NEG NEG NO NA 
9 HICU-20 F 65 8.27 9.6 NA 176 9.5 1.7 X  X 53 6.10 8.7 4.3 3 8.7 2.8 89 313 NEG NO NA 
                         
 
Patients with available follow-up listed by increasing order of serum TSH concentrations measured at hospital admittance. All HICU-20 and LICU-20 patients with thyrotoxicosis 
(n=14), low TSH (n=10) and hypothyroidism (n=7) detected at hospitalisation were contacted for the initial follow-up. At the time of recruitment, thirteen were still hospitalised or in 
rehabilitation, four had died, two were still positive for SARS-CoV-2, three were not reached and one declined. In all cases any pharmacological treatment for Covid-19 was started 
after baseline blood sampling. 
Abbreviations in alphabetical order:  AbTg = autoantibodies to thyroglobulin (negative [NEG] if <60 KIU/L). AbTPO = autoantibodies to thyroid peroxidase (negative [NEG] if <35 
KIU/L). AV = anti-viral drugs (Lopinar/Ritonavir or Remdesivir). A + M = anakinra (interleukin 1 receptor antagonist) and methylprednisolone. CRP = C reactive protein (normal if 
<5 mg/L). FT3 = Free tri-iodothyronine (reference intervals 3.1 - 7.7 pmol/L). FT4 = Free thyroxine (reference intervals 10.3 - 21.9 pmol/L). H = hydroxychloroquine. ID = Patient 
identity code. LYMPH = total lymphocytes count (reference intervals 1.20 - 3.40 *109/L). NA = Not available. TRAb = autoantibodies to TSH receptor (negative [NEG] if <0.55 
KIU/L). TSH = Thyroid Stimulating Hormone (reference intervals 0.28 – 4.30 mIU/L). WBC = total white blood cells count (reference intervals 4.80 - 10.80 *109/L). US = 
Ultrasound. 99mTc = 99m-technetium-pertechnetate.  = low-normal. 
1 Days from baseline TSH to follow-up TSH (F.Up) measurements. 
2 ID1 Could not attend the follow-up visit due to the long Covid-19 clinical course; his thyroid function was re-tested during hospitalisation 
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SUPPLEMENTAL FIGURES 
Figure 2 
 
Imaging of SARS-CoV-2 related subacute thyroiditis obtained in ID6, who had a particularly aggressive clinical course 
of Covid-19 requiring mechanical invasive ventilation. 
Ultrasound imaging of focal hypoechoic areas (white arrows) in the lower and upper portions of the right (panel  A) and 
the upper portion of the left (panel B) thyroid lobes. 
Panel C: Thyroid scintigraphy with 99m-technetium-pertechnetate (99mTc) showing only slightly increased uptake of 
99mTc (0.89%, normal range 0.5-4.0%) in the thyroid gland as compared to that of salivary glands (background). Panel D: 
Thyroid SPECT imaging of two focal areas of reduced 99mTc uptake in the polar portion of the right lobe (red arrow) and 
the middle polar region of the left lobe (red triangles), corresponding to the hypoechoic areas shown at ultrasound. 
  
 16 
ACKNOWLEDGMENTS 
We are extremely grateful to patients who participated in the study and to Valter Monzani, Flora 
Peyvandi, Nicola Montano, Marina Baldini, Anna Ludovica Francanzani, and their dedicated staff 
for taking care of patients in such dramatic Covid-19 epidemic emergency and updating their 
electronic clinical records. 
 
FUNDING 
This work was funded by Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, 
Italy. 
 
